Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 96

    1.

    Rejuvenation in older adults receiving oral ghrelin.

    Gaugg M.

    Ann Intern Med. 2009 May 5;150(9):654; author reply 655. No abstract available. PMID: 19414852 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Rejuvenation in older adults receiving oral ghrelin.

    Webster J.

    Ann Intern Med. 2009 May 5;150(9):654-5; author reply 655. No abstract available. PMID: 19414853 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Rejuvenation in older adults receiving oral ghrelin.

    Rafael H.

    Ann Intern Med. 2009 May 5;150(9):653-4; author reply 655. No abstract available. PMID: 19414850 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Summaries for patients. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.

    [No authors listed]

    Ann Intern Med. 2008 Nov 4;149(9):I-36. No abstract available. PMID: 18981483 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Use of growth hormone secretagogues to prevent or treat the effects of aging: not yet ready for prime time.

    Blackman MR.

    Ann Intern Med. 2008 Nov 4;149(9):677-9. No abstract available. PMID: 18981489 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Sarcopenia and the elusive fountain of youth.

    Hanauer SB.

    Nat Clin Pract Gastroenterol Hepatol. 2009 Jan;6(1):1. No abstract available. PMID: 19127276 [PubMed - indexed for MEDLINE]Related articles

    7.

    Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.

    Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO.

    J Clin Endocrinol Metab. 1996 Dec;81(12):4249-57.PMID: 8954023 [PubMed - indexed for MEDLINE]Related articles

    8.

    Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.

    Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.

    J Clin Endocrinol Metab. 1998 Feb;83(2):362-9.PMID: 9467542 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.

    Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ.

    J Bone Miner Res. 1999 Jul;14(7):1182-8.PMID: 10404019 [PubMed - indexed for MEDLINE]Related articles

    10.

    Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.

    Copinschi G, Van Onderbergen A, L'Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E.

    J Clin Endocrinol Metab. 1996 Aug;81(8):2776-82.PMID: 8768828 [PubMed - indexed for MEDLINE]Related articles

    11.

    Phase I study of oral spirogermanium.

    Harvey J, McFadden M, Smith FP, Joubert L, Schein PS.

    Invest New Drugs. 1990 Feb;8(1):53-6.PMID: 2345069 [PubMed - indexed for MEDLINE]Related articles

    12.

    Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.

    Codner E, Cassorla F, Tiulpakov AN, Mericq MV, Avila A, Pescovitz OH, Svensson J, Cerchio K, Krupa D, Gertz BJ, Murphy G.

    Clin Pharmacol Ther. 2001 Jul;70(1):91-8.PMID: 11452249 [PubMed - indexed for MEDLINE]Related articles

    13.

    Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.

    Svensson J, Carlsson B, Carlsson LM, Jansson JO, Bengtsson BA.

    Clin Endocrinol (Oxf). 1999 Apr;50(4):451-6.PMID: 10468903 [PubMed - indexed for MEDLINE]Related articles

    14.

    Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial.

    von Mühlen D, Laughlin GA, Kritz-Silverstein D, Bergstrom J, Bettencourt R.

    Osteoporos Int. 2008 May;19(5):699-707. Epub 2007 Dec 15.PMID: 18084691 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

    Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO.

    J Clin Endocrinol Metab. 1997 Oct;82(10):3455-63.PMID: 9329386 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.

    Bach MA, Rockwood K, Zetterberg C, Thamsborg G, Hébert R, Devogelaer JP, Christiansen JS, Rizzoli R, Ochsner JL, Beisaw N, Gluck O, Yu L, Schwab T, Farrington J, Taylor AM, Ng J, Fuh V; MK 0677 Hip Fracture Study Group.

    J Am Geriatr Soc. 2004 Apr;52(4):516-23.PMID: 15066065 [PubMed - indexed for MEDLINE]Related articles

    17.

    Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

    Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G, et al.

    Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5.PMID: 7624358 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Constituents of aromatic plants: teucrin A.

    De Vincenzi M, Maialetti F, Silano M.

    Fitoterapia. 2003 Dec;74(7-8):746-9.PMID: 14630189 [PubMed - indexed for MEDLINE]Related articles

    19.

    Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.

    Svensson J, Ohlsson C, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Baylink D, Mohan S, Bengtsson BA.

    J Bone Miner Res. 1998 Jul;13(7):1158-66.PMID: 9661080 [PubMed - indexed for MEDLINE]Related articles

    20.

    Synthesis and biological activities of spiroheterocyclic growth hormone secretagogues.

    Chen MH, Pollard PP, Patchett AA, Cheng K, Wei L, Chan WW, Butler B, Jacks TM, Smith RG.

    Bioorg Med Chem Lett. 1999 May 3;9(9):1261-6.PMID: 10340611 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data